A Phase 2 interventional study of Boswellia serrata extract in Prostate Cancer, sponsored by Brigham and Women's Hospital. Not yet recruiting. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Brigham and Women's Hospital · Phase 2, Interventional, and Supportive care
The goal of this clinical trial is to determine whether Boswellia serrata extract is effective at reducing urinary symptoms in patients undergoing radiation for prostate cancer. The main question it aims to answer is whether patients taking Boswellia report significantly improved urinary symptoms at the 1-week timepoint after taking a minimum of two (2) days of Boswellia treatment.
Participants will follow a treatment plan of 1500 mg of oral Boswellia, taken three times per day, and will report their symptoms and side effects using a specialized questionnaire.
6,484 studies on the registry are indexed under Prostatic Neoplasms; 1,415 are open to participants now.
This study's planned enrollment of 20 is below the median of 58 across 4,908 interventional studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Brigham and Women's Hospital is the lead sponsor of 1,263 studies on the registry; 225 are open to participants now.
Of its 116 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Boswellia 1500 mg three times per day, taken orally for up to 10 weeks
Drug: Boswellia serrata extract
Boswellia 1500 mg three times per day, taken orally for up to 10 weeks
Also known as: Indian Frankincense
Improvements in genitourinary (GU) toxicity from prostate radiation after the initiation of Boswellia as assessed by changes in patient reported outcomes
The primary outcome endpoint will be the percentage of participants who experience improvement in urinary toxicity with Boswellia at the 1-week timepoint after a minimum of 2 days of treatment as determined by participants who mark "Improved" in response to the questionnaire item: "How have your urinary symptoms changed since starting Boswellia?" at the first weekly assessment.
Time frame: 1 week after initiation of oral Boswellia treatment.
No study locations are listed for this record.
Plan to share: No
Start is estimated for Oct 2026; primary completion for Apr 2027, 6 months later.
Of 569 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's planned 6 months is below that.
Counting every sponsor, half of 666 studies reached it within 52 months; a quarter within 34 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Indian frankincense
Brigham and Women's Hospital →